Verseon Corporation showcased its anticancer drug candidates at the BIO-Europe conference in Berlin. Dr. Anirban Datta, Director of Discovery Biology, presented preclinical studies across a range of cancer cell lines, which show that the company's compounds may be especially well-suited for the treatment of multidrug resistant solid tumors. One of the most common ways in which cancer cells render chemotherapies ineffective is by triggering an overproduction of transport proteins that expel many organic substances, including drugs. The preclinical data presented at BIO-Europe demonstrate that Verseon's drug candidates are significantly less susceptible to this mode of tumor resistance. In vitro studies furthermore show that the company's compounds maintain efficacy across multiple cell lines that are resistant to common chemotherapy agents. Verseon's drug candidates inhibit microtubule formation by targeting tubulin. They act against cancer cells by suppressing blood vessel growth and by interrupting the cell division cycle preventing mitosis, both proven treatment strategies for cancer. Lead candidates also show pharmacokinetics suitable for administration as infusion, an important prerequisite for inclusion in infusion-based chemotherapy regimens.